CD274 and gastroesophageal junction adenocarcinoma: Dual inhibition of the VEGF–VEGFR2 and PD-1–PD-L1 (pembrolizumab plus ramucirumab) pathways has been investigated in a multicohort, non-randomized, open-label, phase 1a/b trial and showed a manageable safety profile with favorable antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma [77].